A Phase 2 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus

Brief description of study

The purpose of this study is to learn how well VIB7734 is tolerated in patients with SLE, to determine if it causes any side effects, to learn if it can improve the signs and symptoms of SLE, and to determine if it can help improve the quality of life in patients with SLE. The study will also look at levels of VIB7734, its effects on plasmacytoid dendritic cells and other cells in the blood, and whether your body makes an antibody to VIB7734. In this study, VIB7734 will be compared with a placebo. The placebo is saline (salt water). There are no preservatives in the placebo and it contains no active medicine. Researchers use a placebo to see if a research medicine works better than or is as safe as not taking anything at all.

Clinical Study Identifier: s20-01914
ClinicalTrials.gov Identifier: NCT04925934
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.